NASDAQ:CLSNCelsion Stock Price, Forecast & News

Celsion's stock was trading at $0.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLSN stock has increased by 330.3% and is now trading at $4.26. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Celsion.

Celsion is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) posted its quarterly earnings data on Friday, May, 15th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.03. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 120.14% and a negative net margin of 3,908.00%. View Celsion's earnings history.

Celsion's stock reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

2 brokers have issued 1 year price objectives for Celsion's shares. Their forecasts range from $4.00 to $4.00. On average, they expect Celsion's stock price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 6.1%. View analysts' price targets for Celsion.

News headlines about CLSN stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Celsion earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Celsion.

Some companies that are related to Celsion include Neoleukin Therapeutics (NLTX), Legend Biotech (CALT), Urogen Pharma (URGN), Syndax Pharmaceuticals (SNDX), Athersys (ATHX), Mirum Pharmaceuticals (MIRM), Flexion Therapeutics (FLXN), Clovis Oncology (CLVS), Catalyst Pharmaceuticals (CPRX), Passage Bio (IMRA), Protagonist Therapeutics (PTGX), Viking Therapeutics (VKTX), Zafgen (ZFGN), AC Immune (ACIU) and Satsuma Pharmaceuticals (STSA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Amarin (AMRN), Rexahn Pharmaceuticals (REXN), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY) and Novavax (NVAX).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $4.26.

Celsion has a market capitalization of $135.98 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-16,850,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Celsion employs 29 workers across the globe.

The official website for Celsion is www.celsion.com.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]